Conclusion
Although a growing number of specific and surrogate POCTs are now
available for SARS-CoV2, test performance is variable across the
clinical course. Given existing data, its ease of use and low cost,
FebriDx shows promise as a screening tool for early-stage COVID-19
infection in hospital settings. However, not enough is yet known about
its value in primary care or community settings. Reliable, SARS
CoV2-specific tests – when they become available – are likely to be
the preferred option especially during the autumn and winter months when
the incidence of other, co-circulating respiratory viral infections will
affect the discriminating power of surrogate tests like FebriDx.